Harbir Singh Kohli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Harbir Singh Kohli has a total of 339 co-authors. Here are the top co-authors by number of shared publications:
- Vivekanand Jha
School of Public Health, Imperial College London, London
53 shared publications Vinay Sakhuja
Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
43 shared publicationsKamal Sud
Department of Nephrology, Post Graduate Institute of Medical Education and Research, Chandigarh, India
36 shared publicationsKrishan L. Gupta
Department of Nephrology, PGIMER, Chandigarh, India
23 shared publications- Ritambhra Nada
Department of Histopathology, Post Graduate Institute of Medical Education and Research, Chandigarh 160012, India
22 shared publications - Raja Ramachandran
Post Graduate Institute of Medical Education and Research, Chandigarh, India
21 shared publications
Latest Publications
- 2 September 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
Randomized Controlled Trial Comparing Lactoferrin+Iron with Iron Alone for Iron Deficiency Anemia in CKD
Key Points: Lactoferrin+iron significantly improved hemoglobin and iron indices versus iron alone in CKD patients with iron deficiency anemia. Lactoferrin reduced hepcidin and inflammatory markers, suggesting improved iron utilization using anti-inflammatory mechanisms. Three patients with iron deficiency anemia had elevated inflammatory markers, higher among patients with CKD on dialysis than those not on dialysis. Background: Lactoferrin, a multifunctional iron-binding glycoprotein with anti-inflammatory properties, is reported to be effective in anemia in pregnant women and patients with malignancy but has not been tested elaborately in CKD. Methods: In this randomized, open-label trial, 185 patients (intention-to-treat) with iron-deficiency anemia (hemoglobin [Hb] <10 g/dl, transferrin saturation <20%) were enrolled: 90 with patients with CKD not on dialysis (CKD-ND) and 95 with dialysis-dependent CKD (patients with CKD on dialysis [CKD-5D]). Patients were randomized to receive either oral iron (30 mg/d liposomal iron) or oral iron+lactoferrin (100 mg twice daily) for 3 months. The primary outcome was change in Hb. Secondary outcomes included iron indices and inflammatory markers (C-reactive protein, IL-6, erythrocyte sedimentation rate, and hepcidin). Results: In the intention-to-treat analysis, lactoferrin+iron resulted in significantly greater improvements in Hb and iron parameters than iron alone in both patients with CKD-ND and those with CKD-5D. Mean Hb increased by 1.95±1.19 versus 1.33±0.86 g/dl in patients with CKD-ND and by 1.73±0.96 versus 1.11±0.93 g/dl in patients with CKD-5D receiving lactoferrin+iron and iron alone, respectively. Improvements in iron indices were also greater with add-on lactoferrin treatment. Mean difference in hepcidin levels were −20.24±15.99 versus −16.03±40.65 ng/dl in patients with CKD-ND and −15.29±8.73 versus −20.99±20.16 ng/dl in patients with CKD-5D treated with lactoferrin+iron and iron alone, respectively. Conclusions: Among patients with CKD-associated anemia, adjunctive lactoferrin therapy improved Hb and iron parameters compared with oral iron alone in both non–dialysis-dependent and dialysis-dependent patients. Lactoferrin was also associated with modest improvements in inflammatory status, although effects on individual inflammatory markers were inconsistent. These findings suggest that lactoferrin may be a useful adjunct to oral iron therapy for the management of anemia in CKD, especially in resource-limited settings. Clinical Trial registry name and registration number: Clinical Trials Registry of India, CTRI/2020/04/024746.
- 2 September 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
Randomized Controlled Trial Comparing Lactoferrin+Iron with Iron Alone for Iron Deficiency Anemia in CKD
Key Points: Lactoferrin+iron significantly improved hemoglobin and iron indices versus iron alone in CKD patients with iron deficiency anemia. Lactoferrin reduced hepcidin and inflammatory markers, suggesting improved iron utilization using anti-inflammatory mechanisms. Three patients with iron deficiency anemia had elevated inflammatory markers, higher among patients with CKD on dialysis than those not on dialysis. Background: Lactoferrin, a multifunctional iron-binding glycoprotein with anti-inflammatory properties, is reported to be effective in anemia in pregnant women and patients with malignancy but has not been tested elaborately in CKD. Methods: In this randomized, open-label trial, 185 patients (intention-to-treat) with iron-deficiency anemia (hemoglobin [Hb] <10 g/dl, transferrin saturation <20%) were enrolled: 90 with patients with CKD not on dialysis (CKD-ND) and 95 with dialysis-dependent CKD (patients with CKD on dialysis [CKD-5D]). Patients were randomized to receive either oral iron (30 mg/d liposomal iron) or oral iron+lactoferrin (100 mg twice daily) for 3 months. The primary outcome was change in Hb. Secondary outcomes included iron indices and inflammatory markers (C-reactive protein, IL-6, erythrocyte sedimentation rate, and hepcidin). Results: In the intention-to-treat analysis, lactoferrin+iron resulted in significantly greater improvements in Hb and iron parameters than iron alone in both patients with CKD-ND and those with CKD-5D. Mean Hb increased by 1.95±1.19 versus 1.33±0.86 g/dl in patients with CKD-ND and by 1.73±0.96 versus 1.11±0.93 g/dl in patients with CKD-5D receiving lactoferrin+iron and iron alone, respectively. Improvements in iron indices were also greater with add-on lactoferrin treatment. Mean difference in hepcidin levels were −20.24±15.99 versus −16.03±40.65 ng/dl in patients with CKD-ND and −15.29±8.73 versus −20.99±20.16 ng/dl in patients with CKD-5D treated with lactoferrin+iron and iron alone, respectively. Conclusions: Among patients with CKD-associated anemia, adjunctive lactoferrin therapy improved Hb and iron parameters compared with oral iron alone in both non–dialysis-dependent and dialysis-dependent patients. Lactoferrin was also associated with modest improvements in inflammatory status, although effects on individual inflammatory markers were inconsistent. These findings suggest that lactoferrin may be a useful adjunct to oral iron therapy for the management of anemia in CKD, especially in resource-limited settings. Clinical Trial registry name and registration number: Clinical Trials Registry of India, CTRI/2020/04/024746.
- 21 March 2024
- Published by Wiley in Nephrology
- Vol. 29 (9) , 617-621
Augmented mannose‐binding lectin levels in primary membranous nephropathy: A pilot study
There is evidence to suggest that M‐type phospholipase A2 (PLA2R) antibodies activate the mannose‐binding lectin (MBL) cascade, resulting in glomerular damage and proteinuria in patients with primary membranous nephropathy (PMN). Furthermore, there are few reports indicating that aberrant MBL activation is associated with endothelial dysfunction and accelerated atherosclerosis. While PMN is a common cause of adult nephrotic syndrome, and patients are at increased risk of cardiovascular disease (CVD), there is a lack of research that explores the factors that contribute to this condition. This study aims to determine the MBL levels in PMN and their relation to the clinical activity and endothelial dysfunction in PMN. The MBL levels of 22 biopsy‐confirmed PMN patients were assessed at baseline and after 6 months of immunosuppressive therapy. In order to evaluate endothelial dysfunction in PMN patients, flow‐mediated vasodilation (FMD) was measured at baseline and after treatment. A total of 22 healthy controls were included in this study to measure MBL levels and FMD. A significant difference was observed between MBL levels in PMN patients and healthy controls (p < .01). MBL levels decreased significantly after immunosuppressive therapy (p = .04). The baseline MBL levels and FMD levels exhibited a strong correlation (Spearman correlation coefficient [ρ] = 0.51: p = .01). In conclusion, the study signals the activation of the MBL cascade and its association with endothelial dysfunction in PMN patients.
- 21 March 2024
- Published by Wiley in Nephrology
- Vol. 29 (9) , 617-621
Augmented mannose‐binding lectin levels in primary membranous nephropathy: A pilot study
There is evidence to suggest that M‐type phospholipase A2 (PLA2R) antibodies activate the mannose‐binding lectin (MBL) cascade, resulting in glomerular damage and proteinuria in patients with primary membranous nephropathy (PMN). Furthermore, there are few reports indicating that aberrant MBL activation is associated with endothelial dysfunction and accelerated atherosclerosis. While PMN is a common cause of adult nephrotic syndrome, and patients are at increased risk of cardiovascular disease (CVD), there is a lack of research that explores the factors that contribute to this condition. This study aims to determine the MBL levels in PMN and their relation to the clinical activity and endothelial dysfunction in PMN. The MBL levels of 22 biopsy‐confirmed PMN patients were assessed at baseline and after 6 months of immunosuppressive therapy. In order to evaluate endothelial dysfunction in PMN patients, flow‐mediated vasodilation (FMD) was measured at baseline and after treatment. A total of 22 healthy controls were included in this study to measure MBL levels and FMD. A significant difference was observed between MBL levels in PMN patients and healthy controls (p < .01). MBL levels decreased significantly after immunosuppressive therapy (p = .04). The baseline MBL levels and FMD levels exhibited a strong correlation (Spearman correlation coefficient [ρ] = 0.51: p = .01). In conclusion, the study signals the activation of the MBL cascade and its association with endothelial dysfunction in PMN patients.
- Open Access
- 1 October 2022
- Published by Jaypee Brothers Medical Publishing in Journal of Postgraduate Medicine Education and Research
- Vol. 56 (3) , 129-130
Disseminated Nocardiosis in a Patient with Steroid-dependent Nephrotic Syndrome
- 1 October 2022
- Published by Jaypee Brothers Medical Publishing in Journal of Postgraduate Medicine Education and Research
- Vol. 56 (3) , 129-130
Open AccessDisseminated Nocardiosis in a Patient with Steroid-dependent Nephrotic Syndrome
- 9 August 2022
- Published by Springer Nature in Pediatric Nephrology
- Vol. 38 (4) , 1107-1113
Long-term complications in patients with childhood-onset nephrotic syndrome
Background Reports on long-term complications of childhood-onset nephrotic syndrome (NS), such as obesity, osteoporosis, growth failure, and hypertension, are mostly from developed countries not representing South Asian ethnicities. Furthermore, data on cardiovascular health among patients with childhood-onset NS are limited. Methods This was an observational study involving patients attending a tertiary care center. Patients aged 15 years and older were examined for long-term complications and remission of NS at their visit in December 2021. Childhood-onset NS meant onset of NS before 10 years of age. Long-term complications included obesity, growth failure, low bone mineral density (BMD) Z score, hypertension, and increased carotid intima-media thickness (cIMT). Long-term remission was defined as no relapse for the last \(\ge\) 3 consecutive years without immunosuppressive medication to maintain remission. Results Of 101 patients studied (~ 80% with frequent relapsing (FR)/steroid-dependent (SD) NS), the mean age was 17.6 (± 2.4) years at the time of study. Long-term complications were noted in 89.1% of patients which included one or more of the following: obesity (22.7%), growth failure (31.7%), low BMD Z score (53.5%), hypertension (31.7%), and high cIMT (50.5%). Thirty-nine patients (38.6%) were in long-term remission at the time of the study. Growth failure and low BMD Z scores were less frequent in patients with long-term remission compared to those without long-term remission. Conclusions In patients with childhood-onset NS (predominantly FR/SDNS) who were studied at \(\ge\) 15 years of age, ~ 90% had long-term complications which included high cIMT in 50%. Only ~ 40% were in long-term remission. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information- 9 August 2022
- Published by Springer Nature in Pediatric Nephrology
- Vol. 38 (4) , 1107-1113
Long-term complications in patients with childhood-onset nephrotic syndrome
Background Reports on long-term complications of childhood-onset nephrotic syndrome (NS), such as obesity, osteoporosis, growth failure, and hypertension, are mostly from developed countries not representing South Asian ethnicities. Furthermore, data on cardiovascular health among patients with childhood-onset NS are limited. Methods This was an observational study involving patients attending a tertiary care center. Patients aged 15 years and older were examined for long-term complications and remission of NS at their visit in December 2021. Childhood-onset NS meant onset of NS before 10 years of age. Long-term complications included obesity, growth failure, low bone mineral density (BMD) Z score, hypertension, and increased carotid intima-media thickness (cIMT). Long-term remission was defined as no relapse for the last \(\ge\) 3 consecutive years without immunosuppressive medication to maintain remission. Results Of 101 patients studied (~ 80% with frequent relapsing (FR)/steroid-dependent (SD) NS), the mean age was 17.6 (± 2.4) years at the time of study. Long-term complications were noted in 89.1% of patients which included one or more of the following: obesity (22.7%), growth failure (31.7%), low BMD Z score (53.5%), hypertension (31.7%), and high cIMT (50.5%). Thirty-nine patients (38.6%) were in long-term remission at the time of the study. Growth failure and low BMD Z scores were less frequent in patients with long-term remission compared to those without long-term remission. Conclusions In patients with childhood-onset NS (predominantly FR/SDNS) who were studied at \(\ge\) 15 years of age, ~ 90% had long-term complications which included high cIMT in 50%. Only ~ 40% were in long-term remission. Graphical abstract A higher resolution version of the Graphical abstract is available as Supplementary information- Open Access
- 1 July 2022
- Published by Scientific Scholar in Indian Journal of Medical Research
- Vol. 156 (1) , 14-16
Biomarkers for early diagnosis of diabetic kidney disease: still a long way to go
- 1 July 2022
- Published by Scientific Scholar in Indian Journal of Medical Research
- Vol. 156 (1) , 14-16
Open AccessBiomarkers for early diagnosis of diabetic kidney disease: still a long way to go
- 12 May 2022
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 61 (10) , E314-E315
Visceral infarction in Systemic lupus erythematosus mimicking medium vessel vasculitis
- 12 May 2022
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 61 (10) , E314-E315
Visceral infarction in Systemic lupus erythematosus mimicking medium vessel vasculitis
- Open Access
- 11 May 2022
- Published by Medknow in Indian Journal of Nephrology
- Vol. 32 (5) , 519-520
A structured telemedicine model in the management of COVID-19 infected kidney transplant patients in a tertiary care center in India
Official peer-reviewed open access publication Indian Association of Medical Microbiologists
- 11 May 2022
- Published by Medknow in Indian Journal of Nephrology
- Vol. 32 (5) , 519-520
Open AccessA structured telemedicine model in the management of COVID-19 infected kidney transplant patients in a tertiary care center in India
Official peer-reviewed open access publication Indian Association of Medical Microbiologists
- 5 February 2022
- Published by Springer Nature in Rheumatology International
- Vol. 42 (4) , 749-758
ANCA-associated vasculitis following ChAdOx1 nCoV19 vaccination: case-based review
For the foreseeable future, vaccines are the cornerstone in the global campaign against the Coronavirus Disease-19 (COVID-19) pandemic. As the number and fatalities due to COVID-19 decline and the lockdown anywise rescinded, we recognize an increase in the incidence of autoimmune disease post-COVID-19 vaccination. However, the causality of the most vaccine-induced side effects is debatable and, at best, limited to a temporal correlation. We herein report a case of a 51-year-old gentleman who developed Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis (AAV) 2 week post-COVID-19 vaccination. The patient responded favorably to oral steroids and rituximab. Additionally, we conducted a case-based review of vaccine-associated AAV describing their clinical manifestations and treatment response of this emerging entity.
- 5 February 2022
- Published by Springer Nature in Rheumatology International
- Vol. 42 (4) , 749-758
ANCA-associated vasculitis following ChAdOx1 nCoV19 vaccination: case-based review
For the foreseeable future, vaccines are the cornerstone in the global campaign against the Coronavirus Disease-19 (COVID-19) pandemic. As the number and fatalities due to COVID-19 decline and the lockdown anywise rescinded, we recognize an increase in the incidence of autoimmune disease post-COVID-19 vaccination. However, the causality of the most vaccine-induced side effects is debatable and, at best, limited to a temporal correlation. We herein report a case of a 51-year-old gentleman who developed Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis (AAV) 2 week post-COVID-19 vaccination. The patient responded favorably to oral steroids and rituximab. Additionally, we conducted a case-based review of vaccine-associated AAV describing their clinical manifestations and treatment response of this emerging entity.
- Open Access
- 1 September 2021
- Published by Medknow in Indian Journal of Nephrology
- Vol. 31 (5) , 495-497
Impact of COVID-19 pandemic on nephrology training in an academic center in India: Looking forward through online teaching
J Indian Prosthodont Soc, Official publication of Indian Prosthodontic Society
- 1 September 2021
- Published by Medknow in Indian Journal of Nephrology
- Vol. 31 (5) , 495-497
Open AccessImpact of COVID-19 pandemic on nephrology training in an academic center in India: Looking forward through online teaching
J Indian Prosthodont Soc, Official publication of Indian Prosthodontic Society
- Open Access
- 12 February 2021
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 36 (7) , 1352-1354
Rituximab in primary membranous nephropathy: a comparative study of three dosing regimens
Primary membranous nephropathy (PMN) is the most common cause of adult-onset nephrotic syndrome worldwide [ 1]. Recently, promising results of two randomized trials [ 2, 3] and a few observational studies propounded the use of rituximab as the primary therapy in anti-proteinuric refractory PMN. Authors worldwide administer varying dosage schedules of rituximab in the management of PMN with reasonable success. Into the bargain of efficacy, the cost of rituximab needs to be reckoned with, and a higher dose is extortionate. The economic implication of the therapy needs factoring, especially in a limited-resource setting. In light of these facts, we partook an analysis of three dosing regimens of rituximab therapy viz 375 mg/m2 weekly for 4 weeks (Regimen 1), 1 g on Days 0 and 15 (patients who did not achieve any clinical remission at Month 3 and had a cluster of differentiation (CD19) count of >1% or >5 cells/µL received augmented dosing of rituximab) and CD19-guided rituximab therapy, where patients underwent testing for CD19 at the third to the fourth month of rituximab infusion (375 mg/m2) (Regimen 2), and additional rituximab infusion only if CD19 count of >1% or >5 cells/µL (Regimen 3) (details given in the Supplementary file ).
- 12 February 2021
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 36 (7) , 1352-1354
Open AccessRituximab in primary membranous nephropathy: a comparative study of three dosing regimens
Primary membranous nephropathy (PMN) is the most common cause of adult-onset nephrotic syndrome worldwide [ 1]. Recently, promising results of two randomized trials [ 2, 3] and a few observational studies propounded the use of rituximab as the primary therapy in anti-proteinuric refractory PMN. Authors worldwide administer varying dosage schedules of rituximab in the management of PMN with reasonable success. Into the bargain of efficacy, the cost of rituximab needs to be reckoned with, and a higher dose is extortionate. The economic implication of the therapy needs factoring, especially in a limited-resource setting. In light of these facts, we partook an analysis of three dosing regimens of rituximab therapy viz 375 mg/m2 weekly for 4 weeks (Regimen 1), 1 g on Days 0 and 15 (patients who did not achieve any clinical remission at Month 3 and had a cluster of differentiation (CD19) count of >1% or >5 cells/µL received augmented dosing of rituximab) and CD19-guided rituximab therapy, where patients underwent testing for CD19 at the third to the fourth month of rituximab infusion (375 mg/m2) (Regimen 2), and additional rituximab infusion only if CD19 count of >1% or >5 cells/µL (Regimen 3) (details given in the Supplementary file ).